Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

33.06
-0.7100-2.10%
Post-market: 33.060.00000.00%16:10 EDT
Volume:4K
Turnover:120.06K
Market Cap:42.15M
PE:- -
High:33.72
Open:33.72
Low:32.84
Close:33.77
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.56
T/O Rate:0.28%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Rohto Starts Phase II Trial of RE-01 Cell Therapy for Refractory Ischemic Leg Ulcers

Reuters
·
3 hours ago

Thatch Raises $108 Million at $1 Billion Valuation

Reuters
·
14 hours ago

Thatch: Funding & Participation from the General Partnership, General Catalyst, Andreessen Horowitz, ADP Ventures, Eli Lilly & Others

THOMSON REUTERS
·
14 hours ago

Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send?

TradingKey
·
15 hours ago

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU
·
15 hours ago

Gilead Sciences Expands Lenacapavir Access to 14 Countries

MT Newswires Live
·
Yesterday

LIVE Markets-from Ozempic Face to K-Beauty Factories: the Next Beauty Bet

Reuters
·
Yesterday

Gilead announces agreement with PAHO for lenacapavir access

TIPRANKS
·
Yesterday

Ascendis Pharma Tumbles on Novo Nordisk Collab Termination

Reuters
·
Yesterday

Gilead: Explores Opportunities with Brazilian Health Ministry to Advance Ministry’s Goal of Enabling Local Production of Lenacapavir

THOMSON REUTERS
·
Yesterday

Gilead: Agreement Establishes Regional Pathway Through Pan American Health Organization's Regional Revolving Funds

THOMSON REUTERS
·
Yesterday

Gilead: Co & Paho Announce Partnership to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention Across Latin America & Caribbean

THOMSON REUTERS
·
Yesterday

Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean

Reuters
·
Yesterday

Gilead: to Continue Exploring Opportunities to Work with Paho to Support Country Readiness & Scale-up of Long-Acting Hiv Prevention Access

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Weekly Oral Hiv Prevention Drug Expected to Launch in First Quarter of 2027 - Conf Call

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Hiv Market Growth Should Normalize to 2%-3% Within Next Couple of Quarters - Conf Call

THOMSON REUTERS
·
Yesterday

Eli Lilly Stock (LLY) Gets New Buy Rating as Weight-Loss Drug Sales Accelerate

TIPRANKS
·
Yesterday

Why One of the Last Eli Lilly Holdouts Just Upgraded the Stock to Buy

Dow Jones
·
Yesterday

Ascendis Pharma falls -12.1%

TIPRANKS
·
Yesterday

Legend Biotech Shares Down 1.8%; Co Appoints Ingrid Zhang as CEO

THOMSON REUTERS
·
Yesterday